Selena Juarez Stuart, MD

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

There is not much known about the outcomes of patients on liver dysfunction trials.

This analysis looked to evaluate clinical benefit rates, death on study rates, and rates of grade 3/4 toxicity for patients enrolled on 12 liver dysfunction phase I studies.

Patients were classified by severity of liver dysfunction: mild, moderate, and severe.

Patients in the &lsquo;severe&rsquo; cohort experienced the lowest clinical benefit rates (5%) and highest rates of death (24%).

View more from the 2014 ASCO Annual Meeting

Selena Juarez Stuart, MD | Authors

Articles

Risks and Benefits of Phase I Liver Dysfunction Studies